Anika Therapeutics (ANIK) Assets Average (2011 - 2026)
Anika Therapeutics (ANIK) posted quarterly Assets Average of $181.4 million for Q2 2026, down 4.08% year-over-year from $189.1 million in Q2 2025, and down 1.84% quarter-over-quarter from $184.8 million in Q1 2026.
Anika Therapeutics (ANIK) Assets Average (2011 - 2026) Analysis & Trends
Anika Therapeutics (ANIK) has reported Assets Average for 16 consecutive years, with $181.4 million the latest figure, recorded in Q2 2026.
- In Q2 2026, Assets Average fell 4.08% year-over-year to $181.4 million; the TTM figure through Jun 2026 stood at $181.4 million (down 4.08% YoY), while the FY2025 annual figure was $196.5 million, down 16.98% from the prior year.
- Assets Average retreated to $181.4 million in Q2 2026 per ANIK's latest filing, from $184.8 million in the prior quarter.
- Across five years, Assets Average topped out at $350.9 million in Q3 2022 and bottomed at $181.4 million in Q2 2026.
- Historically, Assets Average has averaged $268.0 million across 5 years, with a median of $265.2 million in 2024.
- Annual changes were most pronounced in 2023 — Assets Average decreased 0.23% — and 2025, when it retreated 28.14%.
- Anika Therapeutics' Assets Average stood at $348.4 million in 2022, then decreased by 14.07% to $299.4 million in 2023, then dropped by 27.5% to $217.1 million in 2024, then dropped by 12.54% to $189.9 million in 2025, then dropped by 4.44% to $181.4 million in 2026.
- Business Quant data shows ANIK's Assets Average at $181.4 million in Q2 2026, $184.8 million in Q1 2026, and $189.9 million in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Assets Avg. (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.98 Bn | 43.02 Bn | - | 43.72 Bn |
| 2 | Teva Pharmaceutical Industries | 43.07 Bn | 39.42 Bn | 2.15 Bn | 39.95 Bn |
| 3 | Zoetis | 31.53 Bn | 29.85 Bn | 1.05 Bn | 15.12 Bn |
| 4 | Takeda Pharmaceutical | 28.60 Bn | 22.80 Bn | 5.10 Bn | 98.59 Bn |
| 5 | United Therapeutics | 22.13 Bn | 19.47 Bn | 683.80 Mn | 6.97 Bn |
| 6 | Viatris | 18.75 Bn | 17.86 Bn | 1.46 Bn | 35.94 Bn |
| 7 | Neurocrine Biosciences | 15.53 Bn | 15.14 Bn | 935.80 Mn | 5.13 Bn |
| 8 | Elanco Animal Health | 11.69 Bn | 11.16 Bn | 798.00 Mn | 13.39 Bn |
| 9 | Dr Reddys Laboratories | 10.13 Bn | 9.97 Bn | - | 5.97 Bn |
| 10 | Anika Therapeutics | 284.33 Mn | 245.92 Mn | 21.24 Mn | 181.43 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 181.43 Mn |
| Mar 31, 2026 | 184.83 Mn |
| Dec 31, 2025 | 189.85 Mn |
| Sep 30, 2025 | 188.56 Mn |
| Jun 30, 2025 | 189.14 Mn |
| Mar 31, 2025 | 196.67 Mn |
| Dec 31, 2024 | 217.07 Mn |
| Sep 30, 2024 | 247.03 Mn |
| Jun 30, 2024 | 263.20 Mn |
| Mar 31, 2024 | 267.19 Mn |
| Dec 31, 2023 | 299.40 Mn |
| Sep 30, 2023 | 328.52 Mn |
| Jun 30, 2023 | 333.98 Mn |
| Mar 31, 2023 | 344.10 Mn |
| Dec 31, 2022 | 348.44 Mn |
| Sep 30, 2022 | 350.93 Mn |
| Jun 30, 2022 | 348.18 Mn |
| Mar 31, 2022 | 344.89 Mn |
| Dec 31, 2021 | 350.23 Mn |
| Sep 30, 2021 | 358.03 Mn |